Our Work in Nephrology

Renal patients are among the most challenging to manage due to multiple co-morbidities and poor outcomes.  Nephrologists see a wide array of patients including those across all five stages of chronic kidney disease, those on dialysis and those with kidney transplants. At Spherix, we have an intimate understanding of the US dialysis market, unparalleled perspective on hospital-based nephrology practice and a unique glimpse into the patient flow within private practice nephrology.

Diseases Covered

Renal Anemia, Chronic Kidney Disease, Dialysis, Diabetic Nephropathy, Hyperkalemia, Hyperphosphatemia, Renal Anemia, SHPT and Lupus Nephritis.

Board of Advisors

Coming soon.

Advocacy Groups

The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with disease in nephrology and those who are close to them.


Pfizer’s Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market – July 31, 2018

Amgen’s Parsabiv Doubles in Most Recent Quarter But Strict Usage Guidelines from Large Dialysis Organizations, DaVita and Fresenius Medical Care, Stifle Potential – July 24, 2018

Biosimilars in Nephrology: Pfizer’s Retacrit Gets FDA Clearance and Prepares to Challenge Amgen’s Anemia Franchise Head On – May 31, 2018

The US Renal Anemia Market Sees Some Shifting As Mircera Use Expands Beyond Fresenius Medical Care Clinics and Auryxia Makes its Debut with a New Iron Deficiency Anemia Indication in the Pre-Dialysis Setting – May 8, 2018


American Society of Nephrology 2018 Conference


NKF logoamerican kidney fund
RPA logo